Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas

Grozinsky-Glasberg, Simona; Barak, Dganit; Fraenkel, Merav; Walter, Martin A; Müeller-Brand, Jan; Eckstein, Joseph; Applebaum, Liat; Shimon, Ilan; Gross, David J (2011). Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer, 117(7), pp. 1377-85. New York, N.Y.: John Wiley & Sons 10.1002/cncr.25646

Full text not available from this repository. (Request a copy)

Gastrinomas, a rare group of neuroendocrine tumors, are responsible for severe peptic disease and diarrhea. Although symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs), data are limited regarding the possible antitumor effect of the peptide receptor radioligand therapy (PRRT) with radiolabeled SSAs in gastrinoma patients. The goal of this study was to assess the effect of PRRT on symptoms, gastrin secretion, and tumor load in patients with progressive malignant gastrinomas.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Walter, Martin Alexander

ISSN:

0008-543X

Publisher:

John Wiley & Sons

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:09

Last Modified:

17 Mar 2015 19:10

Publisher DOI:

10.1002/cncr.25646

PubMed ID:

21425137

Web of Science ID:

000288561700007

URI:

https://boris.unibe.ch/id/eprint/1028 (FactScience: 201701)

Actions (login required)

Edit item Edit item
Provide Feedback